MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate efficacy of the cervical ripening of misoprostol
administration in oral tablet, Angusta® compared with the off-label solution of misoprostol
(Cytotec®) for induction of labor (IOL). Since there is a large cost difference between the
preparations (Angusta® is 43 times more expensive than Cytotec®) it is, from a socio-economic
perspective, of great interest to evaluate if Angusta can be replaced by Cytotec.